Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS

AIDS

Volumn 13, Issue 11, 1999, Pages 1359-1365

  Shikuma, Cecilia M ^a,c   Waslien, Carol ^a,b   McKeague, Jo ^a,b   Baker, Narleen ^a,b   Arakaki, Masakazu ^a   Cui, Xiao Wei ^a,b   Souza, Scott ^a,b   Imrie, Allison ^a,b   Arakaki, Richard ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Leahi Hospital   (United States)

Author keywords

HIV; Insulin; Waist to hip ratio

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INSULIN; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE INTOLERANCE; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL;

ANTHROPOMETRY; BLOOD GLUCOSE; BODY CONSTITUTION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FASTING; HIV INFECTIONS; HIV WASTING SYNDROME; HIV-1; HUMANS; HYPERINSULINISM; INSULIN; MALE; RNA, VIRAL;

EID: 0032819634     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907300-00013     Document Type: Article

References (24)

1. Trends in AIDS Incidence - United States, 1996. MMWR 1997, 46:861-867.
2. Food and Drug Administration. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). PDA Public Health Advisory June 11, 1997.
3. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-714.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
5. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocrine Rev 1996, 17:418-532.
6. McNurlan MA, Carlick PJ, Steigbigel RT, et al. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.; Clin Invest 1997, 100:2125-2132.
7. Gibson RS (Editor). Principles of Nutritional Assessment. New York: Oxford University Press; 1990.
8. Lohman T, Roche AF, Mantorell R (Editors). Anthropometrie Standardization Reference Manual. Champaign, IL: Human Kinetics Book; 1988.
9. Hommes MJT, Romijn JA, Endert E, Schattenkerk JKME, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabofcm 1991,40:651-656.
10. Ceffner ME, Yeh DY, Landaw EM. In vitro insulin-like growth factor-l, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993, 34:66-72.
11. Dever L, Oruwari PA, O'Donovan CA, Eng HK. Hyperglycemia associated with protease inhibitors in HIV-infected subjects. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October 1997 [abstract IB-81.
12. Charakhanian S, Salhi Y, Nguye TH, et al. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors. Sixth Conference on Relroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 642].
13. Walli RK, Herfort O, Michl CM, et al. Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors. 72tri World AIDS Conference. Geneva, June-July 1998 [abstract 41177].
14. Walli K, Michl CM, Seberer S, et al. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 (abstract 645].
15. Glesby M, Desai A, Erbelding E, Kostman J. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 650].
16. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. lancet 1998, 351:871-87.
17. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. A/D51998,12:F37-F39.
18. Saint-Marc T, Poizot-Martin I, Partisani M, Fabre J, Touraine JL. A syndrome of lipodyslrophy in patients receiving a stable nucleoside-analogue therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 6531.
19. Madge S, Kinloch-De Loes S, Tyrer M, Johnson MA. Lypodystrophy syndrome (IS) in patients on reverse transcriptase inhibitors. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 654].
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
21. Hellerstein MK. Endocrine Abnormalities. In The AIDS Knowledge Base. Edited by Cohen PT, Sande MA, Volberding PA. Boston: Little, Brown & Co.; 1994:5.15-5-5.15-6.
22. Chan JCN, Cockram CS, Critchley JAJH. Drug-induced disorders of glucose metabolism - mechanisms and management. Drug Safety 1996, 15: 135-157.
23. Jain P, Cirardi LS, Sharman L, Berelowicz M, Smith LC. Insulin resistance and development of diabetes mellitus associated with megestrol acetate therapy. Postgrad Med I 1996, 72: 365-367.
24. Reaven CM. Role of insulin resistance in human disease (Banting Lecture). Diabetes 1988, 37:1595-1607.